BioMarin to Record $283M 3Q Charge from Alesta Acquisition

BioMarin Pharmaceutical expects to record $283 million in pre-tax charges in the third quarter related to its recent acquisition of Alesta Therapeutics, primarily due to in-process research and development costs.